Alectinib vs Crizotinib in Treatment-Naive ALK+ NSCLC
Alectinib vs Crizotinib in Treatment-Naive ALK+ NSCLC: CNS Efficacy Result From The ALEX Study [1298O_PR]
Potential Biomarkers of Immunotherapy in NSCLC
Comprehensive Genomic Profiling (CGP) Uncovered Potential Biomarkers of Immunotherapy in NSCLC – Good Predictive Markers: TMB-H, BRAF and MET; Poor Predictive Marker: STK11 [1138PD]
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
Lancet Oncol 2017；Published Online November 9, 2017 http://dx.doi.org/10.1016/S1470-2045(17)30690-3
Monthly updates of NSCLC treatment and research from major journals: issue Dec 2017
This article summaries recent progresses published in high impact journals on lung cancer research and treatment. Kindly provided by Ms. Dandan Hu (胡丹丹), a MSI from Roche China, will continually update for every month. Articles in Chinese.